Europe
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.
Bristol Myers Squibb and bluebird bio are eying a potential quick approval for a CAR-T treatment for multiple myeloma after the U.S. Food and Drug Administration accepted the Biologics License Application under priority review.
More than 150 countries have signed on to a World Health Organization program to ensure global access to a COVID-19 vaccine, however, the United States, Russia and China refrained from signing the agreement.
Tagrisso demonstrated an 82% reduction in the risk of central nervous system recurrence or death. The safety and tolerability of the product in the Phase III trial was consistent with previous trials in the metastatic EGFRm NSCLC setting.
Swiss pharma giant Roche acquired Ireland’s Inflazome and its NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases for €380 million (about $451 million) in an upfront payment.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.
PRESS RELEASES